Clinical trial · Interventional
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Camrelizumab Combined With Chemotherapy for Adjuvant Treatment of Cervical Cancer Patients With Pathologically Confirmed Lymph Node Positivity After Stage Surgery: A Prospective, Single-Arm, Multicenter, Phase II Clinical Trial
NCT07167160CI-TRIAL-00099282recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Immunochemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Camrelizumab combined with chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- chemotherapy group
- interventionNames
- Drug: Camrelizumab combined with chemotherapy
Primary outcomes (1)
- measure
- 3-year disease-free survival rate
- timeFrame
- from enrollment until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 100 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery; 2. Positive PD-L1 expression; 3. ECOG score ≤1 Exclusion Criteria: 1. Positive parametrium or surgical margin; 2. Incomplete radical surgery; 3. Residual target lesions; 4. Active autoimmune disease or autoimmune disease requiring systemic treatment; 5. Previous treatment with immune checkpoint inhibitors.
References
Publications (1)
- DERIVEDChen L, Chen T, Tu N, Dong L, Zhang Y, Wang H, Shen Y. Camrelizumab combined with chemotherapy as postoperative adjuvant therapy after radical surgery for cervical cancer patients with pathologically positive lymph nodes: a prospective multicenter phase II clinical trial. J Gynecol Oncol. 2026 Jul 9. doi: 10.3802/jgo.2027.38.e1. Online ahead of print. PMID 42471761